Evidence map›Paper›PMID 28640888›Full record

ArticlePloS one2017

Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.

Ahmed Alhusban, Anna Kozak, Bindu Pillai, Heba Ahmed, Mohammed A Sayed, Maribeth H Johnson, Tauheed Ishrat, Adviye Ergul, Susan C Fagan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Depression and Cardiovascular Disease: The Viewpoint of Platelets.International journal of molecular sciences · 2020
    Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ahmed AlhusbanProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Anna KozakProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Bindu PillaiProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Heba AhmedProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Mohammed A SayedProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Maribeth H JohnsonDepartments of Biostatistics, Medical College of Georgia, Augusta University, Augusta, Georgia, Unites States of America.
Tauheed IshratProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Adviye ErgulProgram in Clinical and Experimental Therapeutics- Charlie Norwood VA Medical Center and College of Pharmacy, University of Georgia, Augusta, Georgia, United States of America.
Susan C FaganDepartments of Biostatistics, Medical College of Georgia, Augusta University, Augusta, Georgia, Unites States of America.
Charlie Norwood VA Medical Center · USUniversity of Georgia · USAugusta University · US

Funding

Vascular Injury and Recovery in Diabetic Ischemic StrokeR01NS083559 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE · 2014 to 2018
$1.9M
Mechanisms of Vascular Protection after Acute StrokeR01NS063965 · NINDS · UNIVERSITY OF GEORGIA · PI FAGAN, SUSAN C · 2009 to 2013
$1.4M
Cerebrovascular mechanisms of ischemic injury in diabetesR03NS054688 · NINDS · AUGUSTA UNIVERSITY · PI ERGUL, ADVIYE · 2007 to 2008
$147k
Cerebral Arteriole Structure/Function in Diabetic Ischemic Brain InjuryI01BX000347 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI ERGUL, ADVIYE · 2009 to 2025
–
Mechanisms and Consequences of Hypertension after StrokeI01BX000891 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI FAGAN, SUSAN C · 2011 to 2014
–
BLRD VA I01 BX000347BLRD VA I01 BX000891NINDS NIH HHS R01 NS063965NINDS NIH HHS R01 NS083559NINDS NIH HHS R03 NS054688
6 · The paper itself

Abstract

Stroke is a leading cause of adult disability worldwide. Improving stroke outcome requires an orchestrated interplay that involves up regulation of pro-survival pathways and a concomitant suppression of pro-apoptotic mediators. In this investigation, we assessed the involvement of eNOS in the AT1 blocker-mediated protective and pro-recovery effects in animals with hypertension. We also evaluated the effect of acute eNOS inhibition in hypertensive animals. To achieve these goals, spontaneously hypertensive rats (SHR) were implanted with blood pressure transmitters, and randomized to receive either an eNOS inhibitor (L-NIO) or saline one hour before cerebral ischemia induction. After 3 hours of ischemia, animals were further randomized to receive either candesartan or saline at the time of reperfusion and sacrificed either 24 hours or 7 days later. Candesartan induced an early protective effect that was independent of eNOS inhibition (50% improvement in motor function). However, the protective effect of candesartan was associated with about five fold up regulation of BDNF expression and about three fold reduction in ER stress markers, in an eNOS dependent manner. The early benefit of a single dose of candesartan, present at 24 hours after stroke, was diminished at 7 days, perhaps due to a failure to induce an angiogenic response in these hypertensive animals. In conclusion, our findings demonstrate an early prorecovery effect of candesartan at both functional and molecular levels. Candesartan induced prorecovery signaling was mediated through eNOS. This effect was not maintained at 7 days after experimental ischemia.

Indexed as

Acute DiseaseAngiotensin II Type 1 Receptor BlockersAnimalsBenzimidazolesBiphenyl CompoundsBlood VesselsBrain-Derived Neurotrophic FactorEndoplasmic Reticulum StressGene Expression RegulationHypertensionMaleNerve Growth FactorsNeuroprotective AgentsNitric Oxide Synthase Type INitric Oxide Synthase Type IIINogo ProteinsAngiotensin II Type 1 Receptor BlockersBenzimidazolesBiphenyl CompoundsBrain-Derived Neurotrophic FactorcandesartanNerve Growth FactorsNeuroprotective AgentsNitric Oxide Synthase Type INitric Oxide Synthase Type IIINogo ProteinsNtrk2 protein, ratProtein-Tyrosine KinasesReactive Nitrogen SpeciesReceptor, Angiotensin, Type 1Receptor, trkBTetrazoles

Identifiers

PMID28640888
PMCPMC5480858
OpenAlexW2722505563

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.